Anaptysbio, Inc (ANAB) — SEC Filings
Anaptysbio, Inc (ANAB) — 37 SEC filings. Latest: 4 (Apr 22, 2026). Includes 16 8-K, 7 SC 13G/A, 6 10-Q.
View Anaptysbio, Inc on SEC EDGAR
Overview
Anaptysbio, Inc (ANAB) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 8-K filed on Nov 26, 2025: AnaptysBio, Inc. filed an 8-K on November 26, 2025, reporting on events that occurred on the same date. The filing primarily concerns Regulation FD disclosures and includes financial statements and exhibits. No specific financial figures or material events were detailed in the provided excerpt.
Sentiment Summary
Across 37 filings, the sentiment breakdown is: 1 bearish, 34 neutral, 2 mixed. The dominant filing sentiment for Anaptysbio, Inc is neutral.
Filing Type Overview
Anaptysbio, Inc (ANAB) has filed 1 4, 16 8-K, 6 10-Q, 2 DEF 14A, 2 10-K, 7 SC 13G/A, 1 SC 13D/A, 2 SC 13G with the SEC between Jan 2024 to Apr 2026.
Filings by Year
Recent SEC Filings (37)
Risk Profile
Risk Assessment: Of ANAB's 23 recent filings, 1 were flagged as high-risk, 9 as medium-risk, and 13 as low-risk. The overall risk profile suggests relatively low risk with generally favorable filings.
Financial Highlights
| Metric | Value |
|---|---|
| Revenue | $76.320M |
| Net Income | $15.113M |
| EPS | $0.54 |
| Debt-to-Equity | N/A |
| Cash Position | $109.833M |
| Operating Margin | N/A |
| Total Assets | $353.098M |
| Total Debt | N/A |
Key Executives
- Daniel Faga
- Hamza Suria
- James J. Frolik, Esq.
- Anthony J. Caldwell, Esq.
Industry Context
AnaptysBio operates in the highly competitive biotechnology sector, focusing on developing therapeutics for autoimmune and inflammatory diseases. The industry is characterized by long development cycles, significant R&D investment, and reliance on strategic partnerships and potential acquisitions for growth and market access. Key trends include advancements in biologics, personalized medicine, and the increasing importance of collaborations for smaller biotechs to fund pipeline development.
Top Tags
8-K (5) · disclosure (5) · financials (4) · sec-filing (4) · 8-k (3) · Biotechnology (3) · Pharmaceuticals (3) · AnaptysBio (3) · regulatory (2) · Drug Development (2)
Key Numbers
| Metric | Value | Context |
|---|---|---|
| Net income for Q3 2025 | $15.113M | Significant improvement from a net loss of $32.851M in Q3 2024 |
| Collaboration revenue for Q3 2025 | $76.320M | More than doubled from $30.017M in Q3 2024 |
| Net loss for nine months ended Sept 30, 2025 | $62.846M | Reduced from $123.447M in the prior year period |
| Cash and cash equivalents as of Sept 30, 2025 | $109.833M | Decreased from $123.080M at Dec 31, 2024 |
| Repurchases and retirements of common stock for nine months ended Sept 30, 2025 | $65.242M | Significant use of cash in financing activities |
| Total stockholders' deficit as of Sept 30, 2025 | $(29,416)K | Shift from $70,868K total stockholders' equity at Dec 31, 2024 |
| Net cash used in operating activities for nine months ended Sept 30, 2025 | $78.300M | Increased from $68.665M in the prior year period |
| Q2 2025 Collaboration Revenue | $95,000 | Represents a 64% decrease from Q2 2024. |
| Q2 2024 Collaboration Revenue | $264,000 | Baseline for comparison, showing a significant drop in 2025. |
| Q2 Revenue Decrease | 64% | Indicates substantial volatility and risk in primary revenue stream. |
| H1 2025 Collaboration Revenue | $404,000 | Shows a 10.7% increase compared to H1 2024, contrasting with the quarterly decline. |
| H1 2024 Collaboration Revenue | $365,000 | Baseline for comparison for the six-month period. |
| H1 Revenue Increase | 10.7% | Despite the Q2 drop, the six-month period shows growth, suggesting uneven revenue recognition. |
| Fiscal Year | 2024 | Period covered by the compensation data |
| Filing Date | 20250429 | Date the DEF 14A was submitted to the SEC |
Related Companies
Frequently Asked Questions
What are the latest SEC filings for Anaptysbio, Inc (ANAB)?
Anaptysbio, Inc has 37 recent SEC filings from Jan 2024 to Apr 2026, including 16 8-K, 7 SC 13G/A, 6 10-Q. Each filing includes an AI-generated plain-English summary.
What is the overall sentiment of ANAB filings?
Across 37 filings, the sentiment breakdown is: 1 bearish, 34 neutral, 2 mixed. The dominant sentiment is neutral.
Where can I find Anaptysbio, Inc SEC filings explained simply?
ReadTheFiling provides AI-powered plain-English summaries of all Anaptysbio, Inc (ANAB) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.
What are the key financial highlights for Anaptysbio, Inc?
Key financial highlights from Anaptysbio, Inc's most recent 10-Q include metrics such as revenue, net income, EPS, and debt ratios. Visit the filing detail page for the full breakdown.
What is the investment thesis for ANAB?
The investment thesis for ANAB includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.
Who are the key executives at Anaptysbio, Inc?
Key executives identified across Anaptysbio, Inc's filings include Daniel Faga, Hamza Suria, James J. Frolik, Esq., Anthony J. Caldwell, Esq..
What are the main risk factors for Anaptysbio, Inc stock?
Of ANAB's 23 assessed filings, 1 were flagged high-risk, 9 medium-risk, and 13 low-risk.
What are recent predictions and forward guidance from Anaptysbio, Inc?
Forward guidance and predictions for Anaptysbio, Inc are extracted from SEC filings as they are enriched.